#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Gastrointestinal stromal tumour Erythema multiforme Hereditary ataxia Metastases to central nervous system Acute myeloid leukaemia Mantle cell lymphoma recurrent Huntington's disease Lennox-Gastaut syndrome Dementia with Lewy bodies High-grade B-cell lymphoma Arterial tortuosity syndrome Leiomyosarcoma metastatic Antiphospholipid syndrome Neuroendocrine tumour Thrombocytopenia More trials…

    Learn about Rare Diseases

    Prolymphocytic leukaemia – Life with Disease Kearns-Sayre syndrome – Life with Disease Bronchopulmonary dysplasia – Life with Disease Sarcoidosis – Treatment Metachromatic leukodystrophy – Trials in Disease Undifferentiated sarcoma – Treatment IgA nephropathy – Diagnostics Progressive supranuclear palsy Malignant fibrous histiocytoma – Life with Disease Carcinoid syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ly3556050 Azd3427 VX-407 Pervi-Fus ADX-324 Bt-001 BROLUCIZUMAB Dabrafenib Mesylate Sebetralstat Gliclazide Levoleucovorin Risperidone Lbl-007 Gimeracil Dorocubicel Al8326 Mbf-015 Lumasiran Imsidolimab Charcoal, Activated More therapies…

    Learn about Your Condition

    Milk allergy Leiomyosarcoma recurrent Ear discomfort Metastatic gastric cancer Haemofiltration Intracranial calcification Injury Angiosarcoma recurrent Anorexia nervosa Salivary gland cancer Pleomorphic liposarcoma Vascular calcification Pseudomonas infection Arteriovenous graft thrombosis Andersen-Tawil syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Azienda Sanitaria Universitaria Giuliano Isontina

Azienda Sanitaria Universitaria Giuliano Isontina

Strada Di Fiume 447, Trieste, 34149, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Transplant

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Carfilzomib
    • Lenalidomide
    Italy

  • Study Comparing Shortened vs Standard Chemotherapy with Rituximab for Initial Treatment of High Tumor Burden Follicular Lymphoma in Newly Diagnosed Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Follicular lymphoma
    Investigated Drugs:
    • Vinorelbine
    • Bendamustine
    • Bendamustine Hydrochloride
    Italy

  • Study on Isatuximab and Dexamethasone for Patients with Relapsed Multiple Myeloma Undergoing Stem Cell Transplantation

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Dexamethasone Sodium Phosphate
    • Isatuximab
    Italy

  • Study on L19IL2 and L19TNF Treatment Before Surgery for Patients with Advanced Melanoma

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Malignant melanoma stage III
    Investigated Drugs:
    • Bifikafusp Alfa
    • Onfekafusp Alfa
    France Germany Italy Poland

  • Study of Inhaled Pirfenidone for Patients with Progressive Pulmonary Fibrosis

    Not recruiting

    2 1
    Investigated Diseases:
    • Pulmonary fibrosis
    Investigated Drugs:
    • Pirfenidone
    Belgium France Germany Italy The Netherlands Poland +1

  • Study on the Effectiveness and Safety of Tanimilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

    Not recruiting

    3 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Tanimilast
    Austria Bulgaria Czechia Germany Greece Hungary +6

  • Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Dexamethasone Sodium Phosphate
    • Carfilzomib
    • Dexamethasone
    Belgium Czechia Germany Greece Italy The Netherlands +2

  • Study of Sotatercept for Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension Patients

    Not recruiting

    3 1
    Investigated Drugs:
    • Sotatercept
    Austria Belgium Croatia Czechia Denmark France +7

  • Study of Atezolizumab and Drug Combination for Patients with Relapsed or Refractory Hodgkin’s Lymphoma Eligible for Stem Cell Transplant

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Vinorelbine Tartrate
    • Vinorelbine
    • Atezolizumab
    Italy

  • Study on Prednisone and Vitamin D for Elderly Patients with Diffuse Large B-Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Glycerol
    • Colecalciferol
    • Prednisolone
    Italy
Previous Page
1 … 5 6 7 8 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!